Health

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the efficacy in favor […]

thaipr.net

22 ส.ค. 65

AMETEK Thailand Opens New Office and Centre of Excellence to Provide Customers in Southeast Asia with AMETEK’s latest Technology Solutions

AMETEK Thailand is pleased to announce that it has opened a new, state-of-the-art facility in a convenient location in Bangkok that will provide enhanced support for customers throughout the Southeast Asia region. AMETEK Thailand began operations in 2017 and continues to play an important role within AMETEK’s Southeast Asia’s ecosystem. The move to a new […]

thaipr.net

17 ส.ค. 65

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming […]

thaipr.net

17 ส.ค. 65

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall […]

thaipr.net

15 ส.ค. 65

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). This comes only a few months after the company received IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications […]

thaipr.net

10 ส.ค. 65
1 … 62 63 64 65 66 … 128

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.